New inclisiran formula tested for high cholesterol safety
NCT ID NCT07626281
First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This early-stage study tests whether a new version of the cholesterol-lowering drug inclisiran, which includes an ingredient called polysorbate 80, is as safe and works as well as the current version. About 120 healthy adults with moderately high LDL cholesterol will receive a single injection of one of the two formulations. Researchers will compare how the drug moves through the body and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inclisiran (a cholesterol-lowering drug) with or without polysorbate 80
- What this could lead to
- If successful, this could lead to a new formulation of inclisiran that is just as safe and effective as the current one, potentially offering more options for managing high cholesterol.
- What could go wrong
- This is an early Phase 1 study with only 120 healthy volunteers, so results may not apply to all patients. The new formulation might not work as well or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCLISIRAN FORMULATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cardiovasular Renal Metabolism
RECRUITINGSan Antonio, Texas, 78232, United States
-
Lenexa Research Unit
RECRUITINGLenexa, Kansas, 66219, United States
-
Salt Lake City Research Unit
RECRUITINGSalt Lake City, Utah, 84124, United States